www.seikagaku.co.jp/ja/development/policy.html
archives
This URL has 1 public saves. The first save was Apr 21, 2026, 01:52 PM and the latest save was Apr 21, 2026, 01:52 PM.
View recent saves on this domain
Latest saved version
研究開発基本方針 | 研究開発 | 生化学工業株式会社
This is the newest public snapshot for this URL and the best place to start reviewing the page.
Source URL
https://www.seikagaku.co.jp/ja/development/policy.html
About this page
This page outlines Biochem Pharma's R&D fundamental policy. The company leverages advanced carbohydrate science to develop innovative pharmaceuticals addressing unmet medical needs. Key pipeline products include SI-6603 for lumbar disc herniation in the US, targeting FDA approval; SI-449 for adhesion prevention in Japan, planned for 2026 submission; and Gel-One for knee and hip osteoarthritis in Japan. The company focuses on glycosaminoglycans (GAG), accumulating 70+ years of research expertise. R&D emphasizes orthopedic and ophthalmologic disease areas, with expanded focus on emerging fields. Innovative research integrating novel modalities shows progress, supporting global product delivery and pipeline enrichment to serve more patients.
Saved versions
www.seikagaku.co.jp/ja/development/policy.html web archives are listed here. You can still review the saved screenshot and HTML even if the original page disappears.